Po-Han Chou1, Che-Sheng Chu2, Ching-Heng Lin3, Chin Cheng4, Yi-Huey Chen5, Tsuo-Hung Lan6, Min-Wei Huang7. 1. Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Psychiatry, School of Medicine, National Yang Ming University, Taipei, Taiwan. Electronic address: phchou1980@gmail.com. 2. Department of Psychiatry, Puli Branch, Taichung Veterans General Hospital, Nantou County, Taiwan. 3. Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan. Electronic address: epid@vghtc.gov.tw. 4. Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan. 5. Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan. 6. Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Psychiatry, School of Medicine, National Yang Ming University, Taipei, Taiwan. Electronic address: tosafish@gmail.com. 7. Chia-Yi branch, Taichung Veterans General Hospital, Chiayi City, Taiwan.
Abstract
OBJECTIVE: Previous research has suggested a link between typical antipsychotic use and the development of cataracts, but the association between atypical antipsychotics and cataracts remains unclear in schizophrenia (SZ). METHODS: A retrospective nested case-control study was conducted using data from the National Health Insurance Database of Taiwan between the year of 2000 and 2011. A total of 2144 SZ patients with cataracts and 2222 controls matched for age, sex, and index date were included. Antipsychotic exposure was categorized by type and duration, and the association between antipsychotic exposure and cataract development was assessed using a conditional logistic regression analysis. RESULTS: We found that the severity of physical comorbidities, concurrent antidepressant use, and comorbidity with glaucoma or other retinal disorders were associated with an increased risk for cataract development. Alternatively, we did not find significant associations between continuous use of clozapine, risperidone, paliperidone, ziprasidone, olanzapine, quetiapine, amisulpride, zotepine or aripiprazole and risk of cataract development in SZ patients. CONCLUSIONS: We did not detect any association between atypical antipsychotic use and risk of cataract development in SZ patients. Future studies with longitudinal ocular evaluations in patients using atypical antipsychotics are warranted to confirm our findings.
OBJECTIVE: Previous research has suggested a link between typical antipsychotic use and the development of cataracts, but the association between atypical antipsychotics and cataracts remains unclear in schizophrenia (SZ). METHODS: A retrospective nested case-control study was conducted using data from the National Health Insurance Database of Taiwan between the year of 2000 and 2011. A total of 2144 SZ patients with cataracts and 2222 controls matched for age, sex, and index date were included. Antipsychotic exposure was categorized by type and duration, and the association between antipsychotic exposure and cataract development was assessed using a conditional logistic regression analysis. RESULTS: We found that the severity of physical comorbidities, concurrent antidepressant use, and comorbidity with glaucoma or other retinal disorders were associated with an increased risk for cataract development. Alternatively, we did not find significant associations between continuous use of clozapine, risperidone, paliperidone, ziprasidone, olanzapine, quetiapine, amisulpride, zotepine or aripiprazole and risk of cataract development in SZ patients. CONCLUSIONS: We did not detect any association between atypical antipsychotic use and risk of cataract development in SZ patients. Future studies with longitudinal ocular evaluations in patients using atypical antipsychotics are warranted to confirm our findings.